Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 4/2008

01-12-2008 | NON-THEMATIC REVIEW

Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents

Authors: Nicolas Magné, Cyrus Chargari, Eric Deutsch, Pierre Castadot, Mitra Ghalibafian, Jean Bourhis, Christine Haie-Meder

Published in: Cancer and Metastasis Reviews | Issue 4/2008

Login to get access

Abstract

Although conventional multimodality approaches allowed improvement in the prognosis of patients with cervix cancer, several tumors do not respond similarly to standard approaches. Recent advances in basic research and genomics have improved our understanding of the biologic basis of the tumor development and progression. Tumor profiling allows for more selective therapeutic strategies leading to the identification of biomarkers or indicators of treatment response and to increased clinical efficacy through development of targeted therapies. Several markers have been identified, that are involved in cellular proliferation, interaction with angiogenesis, extracellular matrice adhesion/invasion, apoptosis, cell cycle pathways and DNA repair mechanisms. In this report, molecular profiling of uterine cervix carcinoma were reviewed with a special focus on rationally designed target-based anticancer agents, in order to clarify and to summary the present state of art in these particular promising area in cervix cancer management.
Literature
1.
Eifel, P. J. (2005). Chemoradiotherapy for cervical cancer: what next? Journal of Clinical Oncology, 23, 8277–8279.PubMed
2.
Gray, H. J. (2008). Primary management of early stage cervical cancer (IA1-IB) and appropriate selection of adjuvant therapy. Journal of the National Comprehensive Cancer Network, 6, 47–52.PubMed
3.
Moore, D. H. (2008). Chemotherapy for advanced, recurrent, and metastatic cervical cancer. Journal of the National Comprehensive Cancer Network, 6, 53–57.PubMed
4.
5.
Pötter, R., et al. (2006). Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiotherapy Oncology, 78, 67–77.
6.
Lindegaard, J.C., et al. (2008). MRI-Guided 3D Optimization Significantly Improves DVH Parameters of Pulsed-Dose-Rate Brachytherapy in Locally Advanced Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 71, 756–764.
7.
Schlessinger, J. (2000). Cell signaling by receptor tyrosine kinases. Cell, 103, 211–225.PubMed
8.
Bonner, J. A., et al. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine, 354(6), 567–578.PubMed
9.
Cerciello, F., et al. (2007). Is EGFR a moving target during radiotherapy of carcinoma of the uterine cervix? Gynecologic Oncology, 106(2), 394–399.PubMed
10.
Huang, S. M., Bock, J. M., & Harari, P. M. (1999). Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Research, 59, 1935–1940.PubMed
11.
Kersemaekers, A. M., et al. (1999). Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clinical Cancer Research, 5(3), 577–586.PubMed
12.
Pillai, M. R., Jayaprakash, P. G., & Nair, M. K. (1998). Tumor-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. Journal of Cancer Research and Clinical Oncology, 124, 456–461.PubMed
13.
Fuchs, I., et al. (2007). The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Research, 27(2), 959–963.PubMed
14.
Gaffney, D. K., et al. (2003). Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. International Journal of Radiation Oncology Biology Physics, 56(4), 922–928.
15.
Kedzia, W., et al. (2002). Immunohistochemical assay of p53, cyclin D1, c-erbB2, EGFr and Ki-67 proteins in HPV-positive and HPV-negative cervical cancers. Folia Histochemica Cytobiologica, 40, 37–41.
16.
Biesterfeld, S., et al. (1999). Absence of epidermal growth factor receptor expression in squamous cell carcinoma of the uterine cervix is an indicator of limited tumor disease. Oncology Reports, 6, 205–209.PubMed
17.
Soto-Cruz, I., et al. (2008). The tyrphostin B42 inhibits cell proliferation and HER-2 autophosphorylation in cervical carcinoma cell lines. Cancer Investigation, 26(2), 136–144.PubMed
18.
Vaidya, A. P., Parnes, A. D., & Seiden, M. V. (2005). Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies. Current Treatment Options in Oncology, 6(2), 103–114.PubMed
19.
Bellone, S., et al. (2007). Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecologic Oncology, 106(3), 513–520.PubMed
20.
Goncalves, A., et al. (2008). A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecologic Oncology, 108(1), 42–46.PubMed
21.
Meric, J. B., et al. (2006). Cyclooxygenase-2 as a target for anticancer drug development. Critical Reviews in Oncology/Hematology, 59, 51–64.PubMed
22.
Ishikawa, H., et al. (2006). Cyclooxygenase-2 impairs treatment effects of radiotherapy for cervical cancer by inhibition of radiation-induced apoptosis. International Journal of Radiation Oncology Biology Physics, 66(5), 1347–1355.
23.
Young, J. L., et al. (2008). Cyclooxygenase-2 in cervical neoplasia: a review. Gynecologic Oncology, 109(1), 140–145.PubMed
24.
Ferrandina, G., et al. (2002). Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. Journal of Clinical Oncology, 20, 973–981.PubMed
25.
Ferrandina, G., et al. (2002). Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications. British Journal of Cancer, 87, 1145–1152.PubMed
26.
Ferrandina, G., et al. (2003). Cyclooxygenase-2 (COX-2) expression in locally advanced cervical cancer patients undergoing chemoradiation plus surgery. International Journal of Radiation Oncology Biology Physics, 55, 21–27.
27.
Chen, H. H., et al. (2005). Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy. International Journal of Radiation Oncology Biology Physics, 63, 1093–1100.
28.
Kim, H. J., et al. (2003). High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. International Journal of Radiation Oncology Biology Physics, 55, 16–20.
29.
Kim, J. Y., et al. (2001). Tumor apoptosis in cervical cancer: its role as a prognostic factor in 42 radiotherapy patients. International Journal of Cancer, 96, 305–312.
30.
Kim, J. Y., et al. (2005). Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecologic Oncology, 97, 337–341.PubMed
31.
Distefano, M., et al. (2004). Concomitant radiochemotherapy plus surgery in locally advanced cervical cancer: update of clinical outcome and cyclooxygenase-2 as predictor of treatment susceptibility. Oncology, 67, 103–111.PubMed
32.
Riou, G., et al. (1987). C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet, 1, 761–763.PubMed
33.
Riou, G. F., Bourhis, J., & Le, M. G. (1990). The c-myc proto-oncogene in invasive carcinomas of the uterine cervix: clinical relevance of overexpression in early stages of the cancer. Anticancer Research, 10, 1225–1231.PubMed
34.
Bourhis, J., et al. (1990). Prognostic value of c-myc proto-oncogene overexpression in early invasive carcinoma of the cervix. Journal of Clinical Oncology, 8, 1789–1796.PubMed
35.
Riou, G., et al. (1988). Somatic deletions and mutations of c-Ha-ras gene in human cervical cancers. Oncogene, 3, 329–333.PubMed
36.
Baykal, C., et al. (2003). Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas. Gynecologic Oncology, 88, 123–129.PubMed
37.
Markowska, J., et al. (2007). Significance of hypoxia in uterine cervical cancer. Multicentre study. European Journal of Gynaecologic Oncology, 28(5), 386–388.
38.
Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Review Cancer, 3, 721–732.
39.
Bachtiary, B., et al. (2003). Overexpression of hypoxia-inducible factor 1 α indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clinical Cancer Research, 9, 2234–2240.PubMed
40.
Birner, P., et al. (2000). Overexpression of hypoxia-inducible factor 1 alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Research, 60, 4693–4696.PubMed
41.
Ishikawa, H., et al. (2004). Expression of hypoxic-inducicle factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. International Journal of Radiation Oncology Biology Physics, 60, 513–521.
42.
Mayer, A., et al. (2004). Lack of correlation between expression of HIF-1α protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Research, 64, 5876–5881.PubMed
43.
Quintero, M., Mackenzie, N., & Brennan, P. A. (2004). Hypoxia-inducible factor 1 (HIF-1α) in cancer. European Journal of Surgical Oncology, 30, 465–468.PubMed
44.
Hutchison, G. J., et al. (2004). Hypoxia-inducible factor 1α expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clinical Cancer Research, 10, 8405–8412.PubMed
45.
Kawanaka, T., et al. (2008). Prognostic significance of HIF-2alpha expression on tumor infiltrating macrophages in patients with uterine cervical cancer undergoing radiotherapy. Journal of Medical Investigation, 55(1–2), 78–86.PubMed
46.
Santin, A. D., et al. (1999). Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstetrics & Gynecology, 94, 78–82.
47.
Lee, J. S., et al. (2002). Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression. Gynecologic Oncology, 85, 469–475.PubMed
48.
Soufla, G., et al. (2005). VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Letters, 221(1), 105–118.PubMed
49.
Bachtiary, B., et al. (2002). Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival. Cancer Letters, 179, 197–03.PubMed
50.
Cheng, W. F., et al. (2000). Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstetrics & Gynecology, 96, 721–726.
51.
Baritaki, S., et al. (2007). Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. International Journal of Oncology, 31(1), 69–79.PubMed
52.
Lee, I. J., et al. (2002). Prognostic value of vascular endothelial growth factor in stage IB carcinoma of the uterine cervix. International Journal of Radiation Oncology Biology Physics, 54, 768–779.
53.
Loncaster, J. A., et al. (2000). Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. British Journal of Cancer, 83, 620–625.PubMed
54.
Kang, J. O., & Hong, S. E. (2004). The prognostic effect of VEGF expression in squamous cell carcinoma of the cervix treated with radiation therapy alone. Journal of Korean Medical Science, 19, 693–697.PubMedCrossRef
55.
Airley, R., et al. (2001). Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clinical Cancer Research, 7(4), 928–934.PubMed
56.
Lee, W. Y., et al. (2008). Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence. Gynecologic Oncology, 108(2), 377–384.PubMed
57.
Goh, P. P., Sze, D. M., & Roufogalis, B. D. (2007). Molecular and cellular regulators of cancer angiogenesis. Current Cancer Drug Targets, 7(8), 743–758.PubMed
58.
Polette, M., et al. (2004). Tumour invasion and matrix metalloproteinases. Critical Reviews in Oncology Hematology, 49, 179–186.
59.
Raza, S. L., & Cornelius, L. A. (2000). Matrix metalloproteinases: pro- and anti-angiogenic activities. Journal of Investigative Dermatology Symposium Proceeding, 5, 47–54.
60.
Lizarraga, F., et al. (2005). Tissue inhibitor of metalloproteinases-4 is expressed in cervical cancer patients. Anticancer Research, 25, 623–627.PubMed
61.
Zhang, Y., et al. (2008). Adenovirus carrying TIMP-3: a potential tool for cervical cancer treatment. Gynecologic Oncology, 108(1), 234–240.PubMed
62.
Davidson, B., et al. (1999). MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma—a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecologic Oncology, 73(3), 372–382.PubMed
63.
Zhai, Y., et al. (2005). Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion. Cancer Research, 65(15), 6543–6550.PubMed
64.
Yaldizl, M., et al. (2005). Expression of E-cadherin in squamous cell carcinomas of the cervix with correlations to clinicopathological features. European Journal of Gynaecologic Oncology, 26, 95–98.
65.
Kaplanis, K., et al. (2005). E-cadherin expression during progression of squamous intraepithelial lesions in the uterine cervix. European Journal of Gynaecologic Oncology, 26(6), 608–610.
66.
Van Aarsen, L. A., et al. (2008). Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Research, 68(2), 561–570.PubMed
67.
Hazelbag, S., et al. (2007). Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. Journal of Pathology, 212(3), 316–324.PubMed
68.
Hazelbag, S., et al. (2004). Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. International Journal of Cancer, 112, 1020–1028.
69.
Bouda, J., et al. (2005). CD44v6 as a prognostic factor in cervical carcinoma FIGO stage IB. Anticancer Research, 25, 617–622.PubMed
70.
Speiser, P., et al. (1997). CD44 is an independent prognostic factor in early-stage cervical cancer. International Journal of Cancer, 74(2), 185–188.
71.
Costa, S., et al. (2001). CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma. Gynecologic Oncology, 80, 67–73.PubMed
72.
Beskow, C., et al. (2006). Expression of DNA damage response proteins and complete remission after radiotherapy of stage IB-IIA of cervical cancer. British Journal of Cancer, 94(11), 1683–1689.PubMed
73.
Lee, J. M., & Bernstein, A. (1995). Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Reviews, 14(2), 149–161.PubMed
74.
Cuddihy, A. R., & Bristow, R. G. (2004). The p53 protein family and radiation sensitivity: Yes or no? Cancer Metastasis Reviews, 23(3–4), 237–257.PubMed
75.
Alfsen, G. C., et al. (2003). The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of gynecology and obstetrics stage I and II adenocarcinoma. Cancer, 98(9), 1880–1889.PubMed
76.
Wootipoom, V., et al. (2004). Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. Gynecologic Oncology, 94(3), 636–642.PubMed
77.
Zhou, J. H., et al. (2006). Fas-mediated pathway and apoptosis in normal cervix, cervical intraepithelial neoplasia and cervical squamous cancer. Oncology Reports, 16(2), 307–311.PubMed
78.
Knox, P. G., et al. (2003). Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand. Journal of Immunology, 170(2), 677–685.
79.
Mora, N., Rosales, R., & Rosales, C. (2007). R-Ras promotes metastasis of cervical cancer epithelial cells. Cancer Immunology, Immunotherapy, 56(4), 535–544.PubMed
80.
Rincón-Arano, H., et al. (2003). R-Ras promotes tumor growth of cervical epithelial cells. Cancer, 97(3), 575–585.PubMed
81.
Rotblat, B., et al. (2008). The ras inhibitor farnesylthiosalicylic Acid (salirasib) disrupts the spatiotemporal localization of active ras: a potential treatment for cancer. Methods in Enzymology, 439, 467–489.PubMed
82.
Oka, K., Suzuki, Y., & Nakano, T. (2000). Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone: radiotherapeutic effect and prognosis. Cancer, 88(12), 2766–2773.PubMed
83.
Suzuki, Y., et al. (2004). Immunohistochemical study of cell cycle-associated proteins in adenocarcinoma of the uterine cervix treated with radiotherapy alone: p53 status has a strong impact on prognosis. International Journal of Radiation Oncology Biology Physics, 60, 231–236.
84.
Kim, J. Y., et al. (2007). Clinical significance of p27 and Skp2 protein expression in uterine cervical neoplasm. International Journal of Gynecological Pathology, 26(3), 242–247.PubMed
85.
Wakatsuki, M., et al. (2008). p73 Protein Expression Correlates With Radiation-Induced Apoptosis in the Lack of p53 Response to Radiation Therapy for Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 70(4), 1189–1194.
86.
Santucci, M. A., et al. (2000). Radiation-induced gadd45 expression correlates with clinical response to radiotherapy of cervical carcinoma. International Journal of Radiation Oncology Biology Physics, 46(2), 411–416.
87.
Cerciello, F., et al. (2005). G2/M cell cycle checkpoint is functional in cervical cancer patients after initiation of external beam radiotherapy. International Journal of Radiation Oncology Biology Physics, 62(5), 1390–1398.
88.
Lee, J. S., et al. (2006). Expression of PTEN in the progression of cervical neoplasia and its relation to tumor behavior and angiogenesis in invasive squamous cell carcinoma. Journal of Surgical Oncology, 93, 233–240.PubMed
89.
Cheung, T. H., et al. (2004). Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecologic Oncology, 93(3), 621–627.PubMed
90.
Nair, A., et al. (2003). NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene, 22(1), 50–58.PubMed
91.
Han, S., et al. (2008). PPAR{beta}/{delta}agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3-K and NF-{kappa}B signals. American Journal of Physiology- Lung Cell and Molecular Physiology, 294, L1238–L1249.
92.
Köster, F., et al. (2007). Correlation of DNA mismatch repair protein hMSH2 immunohistochemistry with p53 and apoptosis in cervical carcinoma. Anticancer Research, 27(1A), 63–68.PubMed
93.
Wilson, C. R., et al. (2000). Expression of Ku70 correlates with survival in carcinoma of the cervix. British Journal of Cancer, 83(12), 1702–1706.PubMed
94.
Ayene, I. S., Ford, L. P., & Koch, C. J. (2005). Ku protein targeting by Ku70 small interfering RNA enhances human cancer cell response to topoisomerase II inhibitor and gamma radiation. Molecular Cancer Therapeutics, 4(4), 529–536.PubMed
95.
Harima, Y., et al. (2003). Expression of Ku80 in cervical cancer correlates with response to radiotherapy and survival. American Journal of Clinical Oncology, 26(4), 80–85.
96.
Ishikawa, M., et al. (2006). Overexpression of p16 INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia. International Journal of Gynecological Cancer, 16(1), 347–353.PubMed
97.
Martin, C. M., et al. (2007). Gene discovery in cervical cancer: towards diagnostic and therapeutic biomarkers. Molecular Diagnosis & Therapies, 11(5), 277–290.
98.
Madrigal, M., et al. (1997). In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma. Gynecological Oncology, 64(1), 18–25.
99.
Sima, N., et al. (2007). Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecological Oncology, 106(2), 299–304.
100.
Tan, T. M., & Ting, R. C. (1995). In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Research, 55(20), 4599–4605.PubMed
101.
de Wilde, J., et al. (2008). Gene expression profiling to identify markers associated with deregulated hTERT in HPV-transformed keratinocytes and cervical cancer. International Journal of Cancer, 122(4), 877–888.
102.
Amine, A., et al. (2006). Cidofovir administered with radiation displays an antiangiogenic effect mediated by E6 inhibition and subsequent TP53-dependent VEGF repression in HPV18+ cell lines. Radiation Research, 166(4), 600–610.PubMed
103.
Abdulkarim, B., et al. (2002). Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene, 21(15), 2334–2346.PubMed
104.
Harima, Y., et al. (1999). Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer. British Journal of Cancer, 81(1), 108–113.PubMed
105.
Harima, Y., et al. (2000). Loss of heterozygosity on chromosome 6p21.2 as a potential marker for recurrence after radiotherapy of human cervical cancer. Clinical Cancer Research, 6(3), 1079–1085.PubMed
106.
Kozlowski, L., et al. (2006). Loss of heterozygosity on chromosomes 2p, 3p, 18q21.3 and 11p15.5 as a poor prognostic factor in stage II and III (FIGO) cervical cancer treated by radiotherapy. Neoplasma, 53(5), 440–443.PubMed
107.
Rao, P. H., et al. (2004). Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BioMed Central Cancer, 4, 5.PubMed
108.
Terra, A. P., et al. (2007). Aberrant promoter methylation can be useful as a marker of recurrent disease in patients with cervical intraepithelial neoplasia grade III. Tumori, 93(6), 572–579.PubMed
109.
Lindström, A. K., et al. (2007). Predicting the outcome of squamous cell carcinoma of the uterine cervix using combinations of individual tumor marker expressions. Anticancer Research, 27(3B), 1609–1615.PubMed
110.
Narayan, G., et al. (2007). Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer, 46(4), 373–384.PubMed
111.
Achary, M. P., et al. (2000). Cell lines from the same cervical carcinoma but with different radiosensitivities exhibit different cDNA microarray patterns of gene expression. Cytogenetics and Cell Genetics, 91(1–4), 39–43.PubMed
112.
Chao, A., et al. (2006). Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. International Journal of Cancer, 119(1), 91–98.
113.
Chen, Y., et al. (2003). Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Research, 63(8), 1927–1935.PubMed
114.
Gaffney, D. K., et al. (2005). Feasibility of RNA collection for micro-array gene expression analysis in the treatment of cervical carcinoma: a scientific correlate of RTOG C-0128. Gynecological Oncology, 97(2), 607–611.
115.
Collis, S. J., & De Weese, T. L. (2004). Enhanced radiation response through directed molecular targeting approaches. Cancer Metastasis Reviews, 23(3–4), 277–292.PubMed
116.
Gu, W., et al. (2006). Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Therapy, 13(11), 1023–1032.PubMed
117.
Moeller, B. J., Richardson, R. A., & Dewhirst, M. W. (2007). Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Reviews, 26(2), 241–248.PubMed
Metadata
Title
Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents
Authors
Nicolas Magné
Cyrus Chargari
Eric Deutsch
Pierre Castadot
Mitra Ghalibafian
Jean Bourhis
Christine Haie-Meder
Publication date
01-12-2008
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 4/2008
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-008-9162-7

Other articles of this Issue 4/2008

Cancer and Metastasis Reviews 4/2008 Go to the issue

OriginalPaper

Imaging of integrin αvβ3 expression

OriginalPaper

Molecular imaging of epidermal growth factor receptor expression–activity at the kinase level in tumors with positron emission tomography

NON-THEMATIC REVIEW

Caveolin-1 in tumor progression: the good, the bad and the ugly

NON-THEMATIC REVIEW

The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host

Acknowledgments

Biography - Anthony F. Shields, M.D., Ph.D.

NON-THEMATIC REVIEW

Cell cycle control and adhesion signaling pathways in the development of metastatic melanoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits